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Summary
Fragile X syndrome is an X-linked mental retardation
condition that usually is due to a trinucleotide-repeat
expansion in the FMR1 gene. Whereas full-mutation al-
leles (1230 repeats) lead to fragile X syndrome, pre-
mutation alleles (∼60–200 repeats) are apparently non-
penetrant. However, previous studies have suggested
that female premutation carriers may have an increased
incidence of premature menopause. To test this possible
association, we screened for premutation alleles among
216 women with early menopause (at age !47 years),
33 of whom had premature menopause (at age !40
years), as well as among 107 control women, all of
whom were ascertained solely on the basis of age at
menopause. No full-mutation alleles were found; and
only one premutation allele was found, but, it was in a
member of the control group. These results are consis-
tent with what would be expected on the basis of chance
only. Our sample size was sufficient to rule out a x3-
fold increased risk of early menopause and a x9-fold
increased risk of premature menopause due to an FMR1
premutation, under a model considering the risk of both
sporadic and familial early menopause. Likewise, our
results rule out a x4-fold increased risk of familial early
menopause and a x26-fold increased risk of familial
premature menopause, under a less probable model in
which only familial early menopause is considered.
These results indicate that the fragile X premutation is
not a major risk factor for early menopause and suggest
that the risk of premature menopause to fragile
X–premutation carriers may not be as great as that re-
ported elsewhere.
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Introduction
Fragile X syndrome is an X-linked dominant condition
with incomplete penetrance. The syndrome is usually the
result of an expansion of the CGG-repeat tract in the 5′
UTR of the FMR1 gene (Warren and Nelson 1994; War-
ren and Ashley 1995). Normal alleles have 6–54 repeats,
usually with one to three interrupting AGG triplets (Fu
et al. 1991; Snow et al. 1993; Kunst and Warren 1994).
Unstable premutation alleles have ∼50–200 repeats and
are susceptible to expansion when passed from a carrier
female to her offspring (Fu et al. 1991; Snow et al. 1993).
In the general population, ∼1/253 women are carriers
of premutation alleles with 154 repeats (Rousseau et al.
1995; Spence et al. 1996). Full mutations have 1230
repeats (Rousseau et al. 1991), resulting in hypermeth-
ylation of FMR1 and inactivation of transcription (Pier-
etti et al. 1991; Sutcliffe et al. 1992); the consequent
lack of functional FMR protein (FMRP) leads to fragile
X syndrome.
For the past decade, investigators have debated the
possibility of increased incidence of ovarian dysfunction
among carriers of a fragile X mutation. Ovarian re-
sponse to exogenous stimulation reportedly has been
found to be decreased in fragile X carriers (Black et al.
1995). DZ twinning reportedly has been found to be
increased in fragile X carriers (Fryns 1986; Tizzano and
Baiget 1992), and in one study the increase was observed
in premutation carriers but not in full-mutation carriers
(Turner et al. 1994). However, Sherman et al. (1988)
found no significant difference in the twinning rate be-
tween fragile X carriers and carriers of hemophilia A,
another X-linked condition, suggesting that the increase
in twinning observed in other studies may have been a
consequence of the method of ascertainment. In a more
recent study, Sherman et al. (1996) followed the preg-
nancies of fragile X carriers who were known to be
carriers before they became pregnant. In this prospec-
tive-mother design, no increased twinning rate was ob-
served for either premutation or full-mutation carriers.
There also have been case reports of premature ovar-
ian failure (menopause at age !40 years) cosegregating
with a fragile X premutation in families (Conway et al.
1995; Vianna-Morgante et al. 1996). Several reports
have suggested that fragile X carriers have a risk of pre-
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mature ovarian failure that is increased above the risk
in the general population (Cronister et al. 1991;
Schwartz et al. 1994; Partington et al. 1996). All three
of these studies ascertained fragile X–carrier women and
compared their rate of premature ovarian failure with
that of controls or with that of the general population.
Thus, it is possible that these studies faced the same
ascertainment problems seen in the twinning studies dis-
cussed above.
Conway et al. (1995) published a study assessing the
presence of the fragile X premutation among 46 women
with premature ovarian failure, 9 of whom reported a
family history of premature ovarian failure. No pre-
mutation carriers were detected among the 37 women
with sporadic premature ovarian failure. However, 2 of
the 9 women with familial premature ovarian failure
were found to carry the premutation. This study avoided
some of the possible biases involved in the ascertainment
of fragile X carriers but still lacked a comparable control
group. These results failed to be replicated by Martin et
al. (1997), who found no premutation carriers among
21 women with premature ovarian failure, although
only 5 study members reported a family history of pre-
mature ovarian failure. To better investigate the alleged
association between the fragile X premutation and age
at menopause, we have determined the fragile X status
for 216 women with early ovarian failure (menopause
at age !47 years) and for 107 controls. Although we
cannot rule out all ascertainment biases (e.g., incomplete
participation in the study and Boston as the study area),
we have avoided some of the ascertainment issues raised
by previous studies, by ascertaining subjects solely on
the basis of age at menopause and by selecting controls
through the same methods as those used to select cases.
Subjects and Methods
Subjects
From a population-based survey of 10,600 women at
age 45–54 years, in the greater Boston area, 344 cases
with early menopause (average age 42.4 years) and 344
age-matched controls who were still menstruating or
who had had menopause at age 146 years were selected
for the study of epidemiological risk factors. The pro-
tocol, approved by the human-subjects committee of the
Brigham and Women’s Hospital, included collection of
a buffy-coat specimen whenever possible. Findings from
the study included reproductive history (Cramer et al.
1995a) and family history of early menopause (Cramer
et al. 1995b) as risk factors for early menopause. This
study of fragile X premutations included three groups
of women who had a buffy coat available: a so-called
familial group of 108 early-menopause cases with a fam-
ily history of early menopause, a so-called sporadic
group of 108 randomly selected early-menopause cases
with no family history of early menopause, and 108
randomly selected controls with neither early menopause
nor a family history of early menopause.
Within the familial group, 17 women had had men-
opause at age !40 years, 50 women had completed men-
opause at age 40–43 years, and 41 women had had
menopause at age 44–46 years. Within the sporadic
group, 16 women had had menopause at age !40 years,
50 women at age 40–43 years, and 42 women at age
44–46 years. The control women had had menopause
at age 146 years or were still menstruating at the time
of participation in the study. The study participants were
ascertained solely on the basis of age at menopause, as
described elsewhere (Cramer et al. 1995a, 1995b).
In this paper, the terms “premature menopause” and
“premature ovarian failure” are used interchangeably to
refer to the natural completion of menopause at age !40
years. Likewise, the terms “early menopause” and “early
ovarian failure” refer to the natural completion of men-
opause at age !47 years.
DNA Studies
All DNA analyses were performed without knowledge
of the study-group status of the subjects. DNA was ex-
tracted from frozen buffy coats by treatment with pro-
teinase K and RNase, followed by phenol/chloroform
extraction, ethanol precipitation, and resuspension in TE
buffer (10 mM Tris and 1 mM EDTA, pH 8.0). PCR
was performed with the incorporation of a[32P]-dCTP
and by use of the f and c primers, which amplify the
region containing the CGG repeat in the 5′ UTR of
FMR1 (Fu et al. 1991). The PCR conditions were mod-
ified from the conditions described by Brown et al.
(1993) and by Kunst and Warren (1994). Ten microliters
of PCR mix (1.1# PCR Buffer II [Perkin Elmer Cetus],
15% dimethyl sulfoxide [Sigma], 1.875 mM MgCl2 [Per-
kin Elmer Cetus], 0.3 mM each dATP, dCTP, dTTP, and
7-deaza-dGTP [Pharmacia], 0.75 mM each f and c prim-
ers, 1 unit perfect match [Stratagene]/ml, and 0.4 mCi
a[32P]-dCTP/ml) were added to 1 ml of DNA (∼50–200
ng). The tubes were heated in a Perkin Elmer 9600 Ther-
mal Cycler at 95C for 10 min, then at 80C for 5 min.
While holding at 80C, 4 ml of enzyme mix (1# PCR
Buffer II [Perkin Elmer Cetus] and 0.375 units Taq/ml)
were added to each reaction tube. The PCR reaction
consisted of 30 cycles of 94C for 30 s, 65C for 30 s,
and 72C for 90 s; this was followed by a final extension
of 72C for 10 min. The PCR products were run on a
5.1% acrylamide gel with formamide, at 80 W for 4.5
h, along with a sequencing ladder, to determine the num-
ber of repeats in each allele. DNA from a known pre-
mutation carrier with alleles of 29 and ∼85 repeats was
included, in each reaction, as a positive control.
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Figure 1 Distribution of FMR1 trinucleotide-repeat lengths, for all three study groups
To ensure that no underamplified alleles 185 repeats
were missed, apparently homozygous samples that pro-
duced only one band were reanalyzed by a more sensitive
PCR method modified from the study by Brown et al.
(1993). The PCR was performed as described above,
without a[32P]-dCTP and with the following modifica-
tions: the enzyme mix consisted of 0.375 units of
15:1 Taq:Pfu (Stratagene) blend and 1# PCR Buffer II,
and the PCR cycle consisted of 94C for 30 s, 65C for
60 s, and 72C for 120 s. The PCR product was run on
a 6% acrylamide gel, at 80 W for 3.25 h, was blotted
overnight onto a Hybond-N nylon transfer membrane
(Amersham), and was probed with a 32P-end-labeled
(CGG)10 probe for 2.5 h at 63C, in Rapid-hyb buffer
(Amersham). DNA from a known premutation carrier
with a normal allele of 30 repeats and a premutation
allele of ∼100 repeats was included as a positive control.
On the basis of the observed allele distribution in the
study group, we calculated the probability of finding at
least 1 individual of the 324 who was homozygous, for
each of the possible number of repeats within the normal
range. By use of a probability of X10%, individuals
who appeared to be homozygous for the less common
alleles were analyzed further to help determine whether
these individuals were indeed homozygous or whether
they had one allele deleted on one of their X chromo-
somes. These samples were typed for two polymor-
phisms flanking the FMR1 repeat region, FRAX-AC1
and FMRa (Kunst and Warren 1994). One sample that
was apparently homozygous for these markers also was
examined for DXS548 (Riggins et al. 1992) and FRAX-
AC2 (Zhong et al. 1993).
Data Analysis
The frequency of early ovarian failure in the general
population is 10% (Coulam et al. 1986), and 37.5% of
these women report a family history of early ovarian
failure (Cramer et al. 1995b). Using these frequencies,
we calculated the expected frequency of premutation
carriers in each of the three study groups. The calcula-
tions were performed with the assumption that there was
no association between premutation and early ovarian
failure or that having a premutation doubles (or triples,
etc.) the risk of early ovarian failure above that of the
general population. Two different models were used in
these calculations. In model 1, the premutation allele
increases equally the risk of familial early ovarian failure
and of sporadic early ovarian failure. In model 2, the
premutation allele increases only the risk of familial early
ovarian failure. A similar set of calculations was com-
pleted for premature ovarian failure, based on a fre-
quency of premature ovarian failure of 1% and a fre-
quency of family history of same of 37.5% among
women with premature ovarian failure (Cramer et al.
1995b).
Statistical methods were performed as indicated in the
Results section, using an alpha level of .05 to determine
significance. The Bonferroni method was used to correct
for multiple comparisons.
Results
Allele Distributions
In this study, the overall distribution of normal FMR1
alleles was similar to previously reported distributions
(Brown et al. 1996; Meadows et al. 1996). The three
study groups did not differ in allele distribution, by x2
analysis (fig. 1). The rate of homozygosity of FMR1
repeat lengths was 58% in the familial early–ovarian
failure group, 53% in the sporadic early–ovarian failure
group, and 46% in the control group.
Although these rates of repeat homozygosity are not
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Table 1
Proportion of Premutation Carriers Predicted among Women with Familial
or Sporadic Early Menopause or among Controls, at Various Levels of
Relative Risk
RELATIVE
RISK
PROPORTION OF PREMUTATION CARRIERS
(%)
Familial Early
Menopause
Sporadic Early
Menopause Controls
Model 1:
1 .4 .4 .4
2 .8 .8 .4
3 1.2 1.2 .3
4 1.6 1.6 .3
5 2.0 2.0 .2
6 2.4 2.4 .2
7 2.8 2.8 .1
8 3.2 3.2 .1
9 3.6 3.6 .0
Model 2:
1 .4 .4 .4
2 .8 .4 .4
3 1.2 .4 .4
4 1.6 .4 .3
5 2.0 .4 .3
6 2.4 .4 .3
7 2.8 .4 .3
8 3.2 .4 .3
9 3.6 .4 .3
significantly different, by x2 analysis, we characterized
nine women in the study group who appeared to be
homozygous for uncommon FMR1 repeat lengths (i.e.,
alleles for which there was a !10% chance of finding at
least one homozygote in the study group of 324 women,
on the basis of the observed allele frequencies in the
study group). Of these nine women, three were from the
familial early-menopause group, two were from the spo-
radic early-menopause group, and four were from the
control group. To examine the possibility that any of
these individuals carried a deletion encompassing the
FMR1 trinucleotide-repeat region, we analyzed these
samples for two polymorphic loci in the area. FRAX-
AC1 is a dinucleotide polymorphism that is ∼7 kb up-
stream of the FMR1 repeat tract (Richards et al. 1991),
and FMRa is a biallelic marker exhibiting a 1-bp poly-
morphism in intron 1 of FMR1, 6 kb downstream of
the repeat (Kunst and Warren 1994). Three individuals
were heterozygous for FRAX-AC1, and five individuals
were heterozygous for both markers. Hence, it is unlikely
that any of these eight individuals carry a large deletion
of this area. Although this analysis would not have de-
tected a small deletion involving the repeat region, such
deletions cause fragile X syndrome (de Graaff et al.
1995), and none of these individuals reported a family
history of mental retardation. One individual from the
control group was homozygous for both FRAX-AC1
and FMRa, as well as for DXS548 and FRAX-AC2 (150
kb upstream and 11 kb downstream of the repeat, re-
spectively) (Richards et al. 1991; Riggins et al. 1992).
Because we could not rule out the possibility of a deletion
in FMR1 in this individual, she was eliminated from the
control group for the remainder of the study, although
her inclusion would not have modified our conclusions.
Early Menopause and Fragile X Premutations
Among all three groups, only one premutation carrier
was identified. She had alleles with 29 and 61 repeats
and was a member of the control group. Because the
frequency of premutation carriers in the general popu-
lation is ∼1/253 and because there were a total of 323
women in this study, the finding of one premutation
carrier is entirely consistent with the expected results
based on chance only (i.e., no association between
FMR1 premutation carriers and early ovarian failure).
By use of Fisher’s exact test, the observed results were
compared with the expected results from the models de-
scribed in the Subjects and Methods section. Under
model 1, the observed results did not differ significantly
from those expected, under the assumption that there
was no association between premutation and early ovar-
ian failure or that carrying a premutation allele doubles
the chance of early ovarian failure (table 1). However,
the results were significantly different from those pre-
dicted by a x3-fold increased risk of early ovarian fail-
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Table 2
Proportion of Premutation Carriers Predicted among Women with Familial
or Sporadic Premature Menopause or among Controls, at Various Levels of
Relative Risk
RELATIVE
RISK
PROPORTION OF PREMUTATION CARRIERS
(%)
Familial Premature
Menopause
Sporadic Premature
Menopause Controls
Model 1:
1 .4 .4 .4
2 .8 .8 .4
3 1.2 1.2 .4
4 1.6 1.6 .4
5 2.0 2.0 .4
6 2.4 2.4 .4
7 2.8 2.8 .4
8 3.2 3.2 .4
9 3.6 3.6 .4
Model 2:
1 .4 .4 .4
2 .8 .4 .4
3 1.2 .4 .4
4 1.6 .4 .4
5 2.0 .4 .4
6 2.4 .4 .4
7 2.8 .4 .4
8 3.2 .4 .4
9 3.6 .4 .4
10 4.0 .4 .4
20 8.0 .4 .4
26 10.4 .4 .4
ure for premutation carriers. In this study, the power for
detection of a 3-fold increase in risk was 93%.
Under model 2, the observed results were significantly
different from those expected for a x4-fold increased
risk of familial early ovarian failure due to a premutation
(table 1). Under this model, the power for detection of
a 4-fold increase in risk was 86%.
Premature Menopause and Fragile X Premutations
No FMR1 premutation carriers were found among
the subset of 33 samples from women with premature
ovarian failure. As in the case of early ovarian failure,
described above, these results were not significantly dif-
ferent from the results expected if there were no asso-
ciation between FMR1 premutation alleles and prema-
ture ovarian failure. Of the 33 women with premature
ovarian failure, 17 were familial cases. On the basis of
results from the study by Conway et al. (1995), we
would have expected to find four premutation carriers
in our familial premature–ovarian failure group. By use
of Fisher’s exact test, these expected results were found
to be significantly different from the observed results of
no premutation carriers in this group.
Under model 1, the observed results were significantly
different from those expected if the premutation in-
creases the risk of both familial and sporadic premature
ovarian failure by x9-fold above the 1% risk to the
general population (table 2). The power for detection of
a 9-fold increase in the risk of premature ovarian failure
was 93%.
Under model 2, in which only the risk of familial
premature ovarian failure is increased in premutation
carriers, there is an increase in risk that is !26-fold above
the general-population risk of 1% (table 2). Under this
model, the power for detection of a 26-fold increase was
88%.
Discussion
The results of this study do not support the hypothesis
that fragile X–premutation carriers are at a high risk of
early menopause (at age !47 years). The observed results
do not differ significantly from those expected, by
chance, with no association between the premutation
and early menopause. From these results, we can con-
clude that if having a premutation does increase the risk
of early menopause, it increases the risk by !3-fold above
the risk to the general population. These results indicate
a much lower risk of early menopause associated with
a premutation than that found by some previous reports.
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For example, when the frequency of early ovarian failure
in the general English population is also assumed to be
10%, the data reported by Partington et al. (1996) sug-
gest that premutation carriers have at least a 7-fold in-
crease in the risk of early ovarian failure.
Conway et al. (1995) suggested that premutation car-
riers have an increased risk of familial premature ovarian
failure but not of sporadic premature ovarian failure.
Under this model, our results indicate that an increased
risk of familial early ovarian failure due to a premutation
is !4-fold above the risk of familial early menopause in
the general population. However, it seems unlikely that
a premutation would increase just the familial early-
menopause cases. Under the assumption that a premu-
tation increases the risk for early menopause, not all
premutation carriers would have early menopause, and
not all family structures would make familial early ovar-
ian failure obvious; such cases would be ascertained as
sporadic. Therefore, a woman with the premutation and
early menopause may or may not have similarly affected
female relatives.
The actual prevalence of premutation carriers among
the general population is an important factor in the sta-
tistical analysis of the data presented here. The figure
1/253 was derived from two different general-popula-
tion screens (Rousseau et al. 1995; Spence et al. 1996).
The data in the study by Spence et al. (1996) were col-
lected from a Virginia population and therefore probably
represent a reasonable estimate for our study popula-
tion. However, the population screened in the study by
Rousseau et al. (1995) was predominantly French Ca-
nadian, and haplotype analysis of the fragile X families
in this population suggested a possible founder effect.
Consequently, the premutation-carrier prevalence of
1/259, reported by Rousseau et al. (1995), may not re-
flect a general carrier frequency. Sherman (1995) esti-
mated the frequency of premutation carriers in a general
population of primarily northern European descent to
be ∼1/342–875. Repetition of this analysis by use of a
premutation-carrier frequency of 1/342 does not change
the results for the risk of early menopause, under either
model. A carrier frequency of 1/875 only changes the
results for model 2 (familial), in which a x5-fold in-
creased risk of early menopause due to a fragile X pre-
mutation is ruled out.
However, if only the women with menopause at age
!40 years (premature ovarian failure) are included in
our analysis, there is not sufficient power to rule out a
substantial increase in the risk of premature menopause
due to a fragile X premutation. Unlike the results for
the early-menopause analysis discussed above, these re-
sults are significantly affected by the prevalence of fragile
X–premutation carriers. Under model 1 (sporadic and
familial), we can rule out a 9-fold, 15-fold, or 19-fold
increase in premature-menopause risk based on pre-
mutation-carrier frequencies of 1/253, 1/342, and 1/875,
respectively. Under model 2 (familial), a 26–35-fold in-
crease in risk is ruled out, for the three different carrier
frequencies.
Because the fragile X premutation-carrier frequency
of 1/253, used in this analysis, was derived in part from
the study by Spence et al. (1996), it is likely that the
lower frequency of 1/875 represents a conservative es-
timate for our analysis. In their Virginia population,
4/745 women carried FMR1 alleles with 154 repeats,
giving an overall premutation frequency of 1/186 fe-
males. Thus, the results from our analysis using a fre-
quency of 1/253 may be reasonable estimates of the true
population characteristics. The results based on this pre-
mutation-carrier frequency are much lower than those
suggested in previous studies. For example, among pre-
mutation carriers, Partington et al. (1996) found a fre-
quency of premature ovarian failure of 28%. When a
general-population frequency of premature ovarian
failure in the English population is assumed to be 1%,
these results suggest that premutation carriers have an
increased risk of premature ovarian failure that is 28-
fold above that of the general population. The data in
the study by Conway et al. (1995) suggest that pre-
mutation carriers have a 150-fold increased risk for fa-
milial premature ovarian failure. These data predicted
that we would find four premutation carriers among our
17 samples from women with familial premature ovar-
ian failure, a predication that is significantly different
from our observed results of no premutation carriers in
this group.
It is also possible that the results from the early-men-
opause analysis are applicable to premature menopause.
There is no clinical reason to distinguish between the
two categories, and the use of the age of 40 years as a
cutoff for premature ovarian failure is a fairly arbitrary
choice (Alper et al. 1986). Furthermore, among cases
with a family history of early or premature menopause,
Cramer et al. (1995b) found no difference in the pro-
portions of women with menopause at age !40 years,
at age 40–43 years, and at age 44–46 years, suggesting
that a genetic component contributes equally to meno-
pause in all three age groups. Therefore, our data suggest
that the association between fragile X premutations and
premature menopause may not be quite as strong as that
suggested in previous reports.
Conway et al. (1995) proposed that a premutation
allele is underexpressed in fetal ovaries, leading to a re-
duction in the number of oocytes at birth. This hypoth-
esis was used to explain the reported association between
premutation carriers and premature ovarian failure.
However, premutation alleles do not appear to reduce
the expression of the FMR1 gene product, in other tis-
sues (Devys et al. 1993; Feng et al. 1995a, 1995b). More-
over, analysis of the ovaries from a 16-wk-gestation fetus
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carrying a full-mutation allele that did not express
FMRP suggested that the number of oocytes was not
markedly reduced (Malter et al. 1997).
A more congruent explanation is that the FMR1 re-
peat is in linkage disequilibrium with a nearby mutation
that leads to ovarian dysfunction, including decreased
ovarian reserve, increased twinning rates, and premature
menopause. Such a mutation could be at a nearby locus
that is involved in ovarian function, but this hypothesis
makes it difficult to explain the apparently normal ovar-
ian function in full-mutation carriers (Schwartz et al.
1994; Turner et al. 1994) whose full mutation still
should be associated with such a nearby mutant allele.
Alternatively, the mutation could be an unrecognized
mutation within the FMR1 gene itself that either inter-
acts with premutation-sized repeats to cause ovarian
dysfunction or is in linkage disequilibrium with large
repeat tracts. FMR1 is expressed in proliferating germ
cells (Bachner et al. 1993) and, in adult ovaries, in the
granulosa cells of developing follicles (Hinds et al. 1993;
Hergersberg et al. 1995). Therefore, mutations that lead
to an altered pattern of ovarian FMRP expression, such
as promoter mutations, could lead to ovarian dysfunc-
tion in premutation carriers while leaving full-mutation
carriers unaffected, since FMRP is not expressed from
full-mutation alleles (Pieretti et al. 1991; Sutcliffe et al.
1992). This hypothesis is supported by the observations
that the FMR1 repeat is in linkage disequilibrium with
nearby loci (Kunst and Warren 1994; Eichler et al. 1996;
Kunst et al. 1996) and that FMR1 premutations cosegre-
gate with premature menopause, in some fragile X fam-
ilies (Conway et al. 1995; Vianna-Morgante et al. 1996).
Our hypothesis also could explain the different re-
ported levels of association between fragile X premu-
tations and premature menopause, since the populations
chosen may have different proportions of fragile X pre-
mutations that are linked to such a putative genetic fac-
tor leading to ovarian dysfunction. Thus, further studies
of this kind are needed to elucidate the relationship be-
tween fragile X and ovarian function, with special at-
tention given to both population choice and ascertain-
ment. In addition, since most of the premature–ovarian
failure cases in our study had completed menopause in
their 30s, it may be necessary to ascertain women who
have had an even earlier menopause, in order to find
premutation carriers.
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